A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice

References

• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecologic Oncol 2007; 107:S2-5; PMID:17938014; http://dx.doi.org/10.1016/j.ygyno.2007.07.067
   PubMedGoogle Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550-60; PMID:20592731; http://dx.doi.org/10.1038/nrc2886
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science (New York, NY) 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172
   Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
   PubMed Web of Science ®Google Scholar
• Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Micro Environment 2011; 4:361-75; PMID:21626415; http://dx.doi.org/10.1007/s12307-011-0066-7
   PubMedGoogle Scholar
• Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstetrics Gynecol 2009; 21:54-9; PMID:19125004; http://dx.doi.org/10.1097/GCO.0b013e32831a9890
   PubMed Web of Science ®Google Scholar
• Wang HL, Xu H, Lu WH, Zhu L, Yu YH, Hong FZ. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstetrics 2014; 289:155-62; PMID:23912529; http://dx.doi.org/10.1007/s00404-013-2938-1
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008; 82:1968-79; PMID:18057249; http://dx.doi.org/10.1128/JVI.02343-07
   PubMed Web of Science ®Google Scholar
• Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anti Cancer Therapy 2007; 7:1473-86; PMID:17944571; http://dx.doi.org/10.1586/14737140.7.10.1473
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncol 2006; 100:469-78; PMID:16249018; http://dx.doi.org/10.1016/j.ygyno.2005.09.040
   PubMed Web of Science ®Google Scholar
• Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005; 17:170-4; PMID:15766677; http://dx.doi.org/10.1016/j.coi.2005.01.004
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines-hope or hype? Nat Rev Immunol 2014; 14:705-11; PMID:25190285; http://dx.doi.org/10.1038/nri3727
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the α(M)β(2) integrin (CD11b/CD18). J Exp Med 2001; 193:1035-44; PMID:11342588; http://dx.doi.org/10.1084/jem.193.9.1035
   PubMed Web of Science ®Google Scholar
• Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol 2004; 25:92-7; PMID:15102368; http://dx.doi.org/10.1016/j.it.2003.11.008
   PubMed Web of Science ®Google Scholar
• Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321
   PubMed Web of Science ®Google Scholar
• Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005; 65:641-9; PMID:15695409
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Translational Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Swee LK, Guimaraes CP, Sehrawat S, Spooner E, Barrasa MI, Ploegh HL. Sortase-mediated modification of alphaDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc Natl Acad Sci USA 2013; 110:1428-33; PMID:23297227; http://dx.doi.org/10.1073/pnas.1214994110
   PubMed Web of Science ®Google Scholar
• Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011; 108:7131-6; PMID:21467219; http://dx.doi.org/10.1073/pnas.1103869108
   PubMed Web of Science ®Google Scholar
• Cheong C, Choi JH, Vitale L, He LZ, Trumpfheller C, Bozzacco L, Do Y, Nchinda G, Park SH, Dandamudi DB et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010; 116:3828-38; PMID:20668230; http://dx.doi.org/10.1182/blood-2010-06-288068
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
   PubMed Web of Science ®Google Scholar
• Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, Hannaman D, Schlesinger SJ, Mizenina O, Nussenzweig MC et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008; 118:1427-36; PMID:18324335; http://dx.doi.org/10.1172/JCI34224
   PubMed Web of Science ®Google Scholar
• Johnson TS, Mahnke K, Storn V, Schonfeld K, Ring S, Nettelbeck DM, Haisma HJ, Le Gall F, Kontermann RE, Enk AH. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 2008; 14:8169-77; PMID:19088032; http://dx.doi.org/10.1158/1078-0432.CCR-08-1474
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou H, Wang W, Tan W, Fu YX, Zhu M. A novel method for synthetic vaccine construction based on protein assembly. Scientific Reports 2014; 4:7266; PMID:25434527; http://dx.doi.org/10.1038/srep07266
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol (Baltimore, Md: 1950) 2010; 185:3426-35; PMID:20729332; http://dx.doi.org/10.4049/jimmunol.1001205
   PubMed Web of Science ®Google Scholar
• Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Exp Opin Biol Therapy 2008; 8:421-39; PMID:18352847; http://dx.doi.org/10.1517/14712598.8.4.421
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England) 2015; 386:2078-88; PMID:26386540; http://dx.doi.org/10.1016/S0140-6736(15)00239-1
   PubMed Web of Science ®Google Scholar
• Delamarre L, Mellman I, Yadav M. Cancer immunotherapy. Neo approaches to cancer vaccines. Science (New York, NY) 2015; 348:760-1; PMID:25977539; http://dx.doi.org/10.1126/science.aab3465
   Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (New York, NY) 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
   Google Scholar
• Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (New York, NY) 1986; 234:364-8; PMID:2876518; http://dx.doi.org/10.1126/science.2876518
   Google Scholar
• Decatur AL, Portnoy DA. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science (New York, NY) 2000; 290:992-5; PMID:11062133; http://dx.doi.org/10.1126/science.290.5493.992
   Google Scholar
• Sewell DA, Shahabi V, Gunn GR, 3rd, Pan ZK, Dominiecki ME, Paterson Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004; 64:8821-5; PMID:15604239; http://dx.doi.org/10.1158/0008-5472.CAN-04-1958
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, NY) 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
   Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Eng J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Exp Opin Biol Therapy 2013; 13:847-61; PMID:23421934; http://dx.doi.org/10.1517/14712598.2013.770836
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Eng J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74:4042-52; PMID:24812273; http://dx.doi.org/10.1158/0008-5472.CAN-13-2685
   PubMed Web of Science ®Google Scholar
• Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuro Immunol 2004; 155:172-82; PMID:15342209; http://dx.doi.org/10.1016/j.jneuroim.2004.06.013
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{α}+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; http://dx.doi.org/10.1084/jem.20101159
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014; 25:37-48; PMID:24434209; http://dx.doi.org/10.1016/j.ccr.2013.12.004
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34:67-73; PMID:23122052; http://dx.doi.org/10.1016/j.it.2012.10.004
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013; 1:15; PMID:24829751 http://dx.doi.org/10.1186/2051-1426-1-15
   PubMedGoogle Scholar
• Dai B, Xiao L, Bryson PD, Fang J, Wang P. PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines. Mol Ther 2012; 20:1800-9; PMID:22588271; http://dx.doi.org/10.1038/mt.2012.98
   PubMed Web of Science ®Google Scholar
• Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res 2014; 20:5456-67; PMID:24893628; http://dx.doi.org/10.1158/1078-0432.CCR-14-0344
   PubMed Web of Science ®Google Scholar
• Zeng Q, Peng S, Monie A, Yang M, Pang X, Hung CF, Wu TC. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Human Gene Therapy 2011; 22:809-19; PMID:21128743; http://dx.doi.org/10.1089/hum.2010.071
   PubMed Web of Science ®Google Scholar